KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) Restructuring Costs (2016 - 2025)

Resmed's Restructuring Costs history spans 9 years, with the latest figure at $5.9 million for Q4 2025.

  • For Q4 2025, Restructuring Costs changed N/A year-over-year to $5.9 million; the TTM value through Dec 2025 reached $23.7 million, up 84653.57%, while the annual FY2025 figure was $2.0 million, 96.84% down from the prior year.
  • Restructuring Costs reached $5.9 million in Q4 2025 per RMD's latest filing, down from $15.8 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $64.2 million in Q4 2023 to a low of $28000.0 in Q2 2024.
  • Average Restructuring Costs over 3 years is $16.5 million, with a median of $8.4 million recorded in 2023.
  • Peak YoY movement for Restructuring Costs: plummeted 99.74% in 2024, then soared 7153.57% in 2025.
  • A 3-year view of Restructuring Costs shows it stood at $64.2 million in 2023, then plummeted by 99.96% to $28000.0 in 2024, then soared by 20971.43% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for RMD's Restructuring Costs are $5.9 million (Q4 2025), $15.8 million (Q3 2025), and $2.0 million (Q2 2025).